Analyst Ratings For BIIB – Biogen (NASDAQ:BIIB)
Today, BIIB – Biogen (NASDAQ:BIIB) stock was downgraded by Barclays from Overweight to Equal Weight with a price target of $295.00.
Some recent analyst ratings include
- 4/5/2018-Barclays was Downgraded by analysts at Barclays from a “Overweight ” rating to a ” Equal Weight” rating. They now have a $295.00 price target on the stock, up previously from $395.00 .
- 3/12/2018-Credit Suisse Group Reiterated Rating of Buy.
- 2/16/2018-Argus was Downgraded by analysts at Argus from a “Buy ” rating to a ” Hold” rating.
Recent Insider Trading Activity For BIIB – Biogen (NASDAQ:BIIB)
BIIB – Biogen (NASDAQ:BIIB) has insider ownership of 0.25% and institutional ownership of 88.93%.
- On 2/27/2018 Alfred Sandrock, EVP, sold 259 with an average share price of $290.83 per share and the total transaction amounting to $75,324.97.
- On 2/20/2018 Alfred Sandrock, EVP, sold 743 with an average share price of $292.00 per share and the total transaction amounting to $216,956.00.
- On 2/15/2018 Alfred Sandrock, EVP, sold 1,294 with an average share price of $298.85 per share and the total transaction amounting to $386,711.90.
- On 1/9/2018 Robert W Pangia, Director, sold 5,832 with an average share price of $329.65 per share and the total transaction amounting to $1,922,518.80.
- On 12/29/2017 Michel Vounatsos, CEO, bought 780 with an average share price of $320.55 per share and the total transaction amounting to $250,029.00.
- On 12/29/2017 Michel Vounatsos, CEO, bought 780 with an average share price of $320.55 per share and the total transaction amounting to $250,029.00.
- On 11/29/2017 Alexander J Denner, Director, bought 30,000 with an average share price of $317.36 per share and the total transaction amounting to $9,520,800.00.
Recent Trading Activity for BIIB – Biogen (NASDAQ:BIIB)
Shares of BIIB – Biogen closed the previous trading session at 267.17 down -5.23 1.92% with 271.8299865722656 shares trading hands.